Cancer name Colon Carcinoma
Cancer Type COCA
Immunotherapy type Cancer Vaccine
Treatment CpDV-IL2-MS
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature MMP-9
Official Symbol MMP9
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Other factors derived from tumor cellsand tumor stromal cells, which play animportant role in forming the microenvironment or suppressing functional immune cells, were examined including VEG-F, SDF-1, FAP, MMP-9, IL-10 and PDL-1. Among them, MMP-9and PDL-1 were significantly reduced by the CpDV-IL2-MS vaccine.
PMID 29193199
Title MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model